rimonabant

CLINICAL USE

Treatment for obesity in conjunction with diet and exercise

DOSE IN NORMAL RENAL FUNCTION

20 mg daily before breakfast

PHARMACOKINETICS

Molecular weight :463.8

%Protein binding :>99.9

%Excreted unchanged in urine : 3

Volume of distribution (L/kg) :Depends on body weight (higher in obese patients)

half-life – normal/ESRD (hrs) :9 days (16 days in obese patients)

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function. Use with caution

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unlikely to be dialysed. Dose as in GFR <10 mL/min

HD :Unlikely to be dialysed. Dose as in GFR <10 mL/min

HDF/high flux :Unknown dialysability. Dose as in GFR <10 mL/min

CAV/VVHD :Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsKetoconazole: concentration of rimonabant increased

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Manufacturer states use contraindicated in CKD 5 due to lack of dataDo not use in patients with major depression or who are on an antidepressant as there is a high risk of depression reported with rimonabant.

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home